HUP0004221A2 - O-Helyettesített hidroxi-kumaranon-származékok, alkalmazásuk tumor- és metasztázis-ellenes gyógyszerkészítmények előállítására és a gyógyszerkészítmények - Google Patents

O-Helyettesített hidroxi-kumaranon-származékok, alkalmazásuk tumor- és metasztázis-ellenes gyógyszerkészítmények előállítására és a gyógyszerkészítmények

Info

Publication number
HUP0004221A2
HUP0004221A2 HU0004221A HUP0004221A HUP0004221A2 HU P0004221 A2 HUP0004221 A2 HU P0004221A2 HU 0004221 A HU0004221 A HU 0004221A HU P0004221 A HUP0004221 A HU P0004221A HU P0004221 A2 HUP0004221 A2 HU P0004221A2
Authority
HU
Hungary
Prior art keywords
medicaments
group
hydroxycumaranone
antimetastatic
derivatives
Prior art date
Application number
HU0004221A
Other languages
English (en)
Inventor
Bernhard König
Ambrogio Oliva
Gianpiero De Cillis
Roberto Di Domenico
Original Assignee
F. Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag. filed Critical F. Hoffmann-La Roche Ag.
Publication of HUP0004221A2 publication Critical patent/HUP0004221A2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

Az (I) általános képletű vegyületek,[mely képletben R és R' jelentése egymástól függetlenül hidrogénatom, 1-6 szénatomosalkil-, sztiril- vagy 3-6 szénatomos cikloalkilcsoport, vagy R és R' aszénatommal együtt, amelyhez kapcsolódik, 3-6 szénatomoscikloalkilcsoportot képez; x értéke 0 vagy 1; A jelentése -(CH2)n-, -(CH2)q-O-(CH2)q- vagy -CH2-A'-CH2- vagy 4-6szénatomos alkeniléncsoport; A' jelentése 3-7 szénatomos cikloalkilcsoport; B jelentése (i) -N(R1)-(CH2)m-N(R2)- csoport, ahol m értéke 2-6; R1 jelentése hidrogénatom, metil-, etil-, propil- vagyizopropilcsoport; és R2 jelentése 1-6 szénatomos alkil-, benzil-, fenil-, naftil- vagyindanilcsoport, amely csoportok helyettesítőt is hordozhatnak; vagy (ii) (A), (B), (C), (D) vagy (E) képletű csoport; T jelentése -CH2-CCH, -CCH, -(CH2)p-R3, -CH=CH-R3, -CH2-NHCO-R3, -(CH2)p-O-R3 vagy -CH(NH2)-CH2R3] (urokináz típusúplazminogénaktivátor) antagonista hatással rendelkeznek éstumorellenes és/vagy metasztázisellenes hatóanyagként alkalmazhatók. Ó
HU0004221A 1997-07-31 1998-07-23 O-Helyettesített hidroxi-kumaranon-származékok, alkalmazásuk tumor- és metasztázis-ellenes gyógyszerkészítmények előállítására és a gyógyszerkészítmények HUP0004221A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97113190 1997-07-31
EP98106946 1998-04-16
PCT/EP1998/004619 WO1999006387A2 (en) 1997-07-31 1998-07-23 O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents

Publications (1)

Publication Number Publication Date
HUP0004221A2 true HUP0004221A2 (hu) 2001-04-28

Family

ID=26145681

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004221A HUP0004221A2 (hu) 1997-07-31 1998-07-23 O-Helyettesített hidroxi-kumaranon-származékok, alkalmazásuk tumor- és metasztázis-ellenes gyógyszerkészítmények előállítására és a gyógyszerkészítmények

Country Status (21)

Country Link
US (1) US6200989B1 (hu)
EP (1) EP1012147B1 (hu)
JP (1) JP3241711B2 (hu)
KR (1) KR100343067B1 (hu)
AR (1) AR013374A1 (hu)
AT (1) ATE308535T1 (hu)
AU (1) AU745839B2 (hu)
BR (1) BR9811589A (hu)
CA (1) CA2296476A1 (hu)
DE (1) DE69832184D1 (hu)
HR (1) HRP20000031A2 (hu)
HU (1) HUP0004221A2 (hu)
ID (1) ID24525A (hu)
IL (1) IL134193A0 (hu)
MA (1) MA26528A1 (hu)
NO (1) NO20000366D0 (hu)
PE (1) PE106099A1 (hu)
PL (1) PL338614A1 (hu)
TR (1) TR200000272T2 (hu)
UY (1) UY25114A1 (hu)
WO (1) WO1999006387A2 (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736869B2 (en) * 1999-01-30 2001-08-02 Roche Diagnostics Gmbh O-substituted hydroxycoumaranone derivatives as antitumor and antimetastatic agents
WO2003046207A2 (en) * 2001-11-27 2003-06-05 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
AU2002358158A1 (en) * 2001-12-19 2003-06-30 D. Collen Research Foundation Use of urokinase receptor antagonists to modulate ischemiareperfusion injury
WO2004076444A2 (en) * 2003-02-25 2004-09-10 F. Hoffmann-La Roche Ag Novel hydroxycoumaranone derivatives as antitumor and antimetastatic
ES2535436T3 (es) * 2006-10-27 2015-05-11 The University Of Tokyo Compuesto amídico o sal del mismo, e inhibidor de la formación de biopelícula, eliminador de biopelícula, y bactericida, utilizando cada uno el compuesto amídico o la sal del mismo
US8258307B2 (en) 2006-11-07 2012-09-04 University Of Tokyo Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
PT109740B (pt) * 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
ES2919779T3 (es) 2017-06-20 2022-07-28 Imbria Pharmaceuticals Inc Derivado de 1-[(2,3,4-trimetoxifenil)metil]-piperazina, composiciones del mismo y métodos para aumentar la eficiencia del metabolismo cardíaco
CA3073656C (en) 2017-09-22 2024-03-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
EP3707135A1 (en) 2017-11-06 2020-09-16 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
MX2020006115A (es) 2017-12-13 2020-11-09 Praxis Biotech LLC Inhibidores de la vía de respuesta al estrés integrada.
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
KR20210021519A (ko) * 2018-06-05 2021-02-26 프락시스 바이오테크 엘엘씨 통합 스트레스 반응 경로의 저해제
US11318133B2 (en) 2019-06-12 2022-05-03 Praxis Biotech LLC Modulators of integrated stress response pathway
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2901336A1 (de) 1979-01-15 1980-07-24 Boehringer Mannheim Gmbh Neue arylether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3209271A1 (de) * 1982-03-13 1983-09-15 Boehringer Mannheim Gmbh, 6800 Mannheim Bicyclische phenolether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3587711T2 (de) * 1984-08-13 1994-04-28 Biotech Australia Pty Ltd Minaktivin.
US5747458A (en) * 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands

Also Published As

Publication number Publication date
PL338614A1 (en) 2000-11-06
AU745839B2 (en) 2002-04-11
NO20000366L (no) 2000-01-25
MA26528A1 (fr) 2004-12-20
AU9155998A (en) 1999-02-22
ATE308535T1 (de) 2005-11-15
KR100343067B1 (ko) 2002-07-03
AR013374A1 (es) 2000-12-27
CA2296476A1 (en) 1999-02-11
JP2001512113A (ja) 2001-08-21
US6200989B1 (en) 2001-03-13
KR20010022362A (ko) 2001-03-15
NO20000366D0 (no) 2000-01-25
PE106099A1 (es) 1999-11-11
UY25114A1 (es) 2001-01-31
HRP20000031A2 (en) 2000-10-31
BR9811589A (pt) 2000-09-19
DE69832184D1 (de) 2005-12-08
ID24525A (id) 2000-07-20
EP1012147A2 (en) 2000-06-28
TR200000272T2 (tr) 2000-09-21
WO1999006387A3 (en) 1999-04-22
WO1999006387A2 (en) 1999-02-11
JP3241711B2 (ja) 2001-12-25
IL134193A0 (en) 2001-04-30
EP1012147B1 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
HUP0004221A2 (hu) O-Helyettesített hidroxi-kumaranon-származékok, alkalmazásuk tumor- és metasztázis-ellenes gyógyszerkészítmények előállítására és a gyógyszerkészítmények
HUP0001993A2 (hu) Fungicid hatású (trifluor-metil-alkil)-amino-triazol 0[1,5-a]pirimidin-származékok, előállításuk és alkalmazásuk
NZ319131A (en) Herbicidal mixtures having a synergistic effect
ATE195724T1 (de) Harnstoff- und amid-derivate mit acat- inhibitorwirkung, ihre herstellung und ihre therapeutische und prophylaktische verwendung
HUP0004082A2 (hu) Adenozinszármazékok, eljárás előállításukra azokat hatóanyagként tartalmazó gyógyszerkészítmények, valamint ilyen hatóanyagok alkalmazása gyógyszerkészítmények előállítására
CA2230936A1 (en) 5-azabicyclo(3.1.0)hexylalkyl-2-piperidones and -glutarimides as neurokinin receptor antagonists
HUP0003743A2 (hu) Rezorcin-származékokat tartalmazó topikális gyógyászati készítmény és ennek alkalmazása embernél bőr színtelenítésére vagy bőr pigmentációjának csökkentésére
HUP0204418A2 (hu) NHE-1 inhibitor hatású N-[(helyettesített öttagú, di- vagy triaza-, kétszeresen telítetlen gyűrű)-karbonil]-guanidin-származékok és alkalmazásuk
HUP0401478A2 (hu) Fungicid hatású pirazolil-karboxanilid-származékok
AU5702996A (en) Oxygen-containing heterocyclic compounds
HUP0402235A2 (hu) 4,4-Difluor-1,2,3,4-tetrahidro-5H-1-benzazepin-származékok és ezek sói és ezeket tartalmazó gyógyszerkészítmények
TW352382B (en) Substituted sulfonimidamides, processes for their preparation, their use as a medicament of diagnostic, and medicament comprising them
HUP0002037A2 (hu) Hidroximsavszármazékok, a vegyületek alkalmazása a mátrix metalloproteináz gátlására alkalmas gyógyászati készítmények előállítására, valamint a vegyületeket tartalmazó gyógyászati készítmények
HUP0000343A2 (hu) 1,3-Propándiol-származékok alkalmazása szervátültetés után fellépő kilökődés megakadályozására
DE69207194D1 (de) Verfahren zur Herstellung von Bacchatin III und von Desacetyl-10-Bacchatin III Derivate
HUP0401235A2 (hu) 5-HT6 receptor affinitással rendelkező arilszulfonil-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HUP0402378A2 (hu) Gyulladáskeltő citokinokat gátló spirociklikus 6,7-dihidro-5H-pirazolo[1,2-a]pirazol-1-onok és az ezeket tartalmazó gyógyszerkészítmények
HUP0402341A2 (hu) Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére
DE69516605T2 (de) Camptothecin-Derivate, ihre Herstellung und Antitumormittel
NO955197L (no) Nye carbosykliske nukleoside midler som er anvendbare som selektive inhibitorer av pro-inflammatoriske cytokiner
HUP9901137A2 (hu) N-szulfonil- és N-szulfinil-aminosav-származékok, előállításuk, a vegyületeket hatóanyagként tartalmazó mikrobicid készítmények és alkalmazásuk
ES2112151A1 (es) Nuevos compuestos homoquirales para la preparacion de ketoconazol, terconazol y antifungicos relacionados, procedimiento para su fabricacion y utilizacion de los mismos.
HUP9900246A2 (hu) Liofilizált tio-xantenont tartalmazó tumorellenes gyógyszerkészítmények
HUP0001010A2 (hu) Benzimidazol-származékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
CO5011097A1 (es) Derivados de 8-azabiciclo [3.2.1]octan-3-metanamina .